Compliance with pregnancy prevention plan recommendations in 8672 French women of childbearing potential exposed to acitretin

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 5, 2015, Pages 526-533

  Raguideau, Fanny ^a   Mezzarobba, Myriam ^b   Zureik, Mahmoud ^a   Weill, Alain ^b   Ricordeau, Philippe ^b   Alla, François ^b  

^a Unité d'hémovigilance Agence nationale de sécurité du médicament et des produits de santé   (France)

^b Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

Author keywords

Acitretin use; Cohort; Pharmacoepidemiology; Pregnancies; Pregnancy Prevention Plan recommendations

Indexed keywords

ANTIPSORIASIS AGENT; CHORIONIC GONADOTROPIN BETA SUBUNIT; CORTICOSTEROID; CYCLOSPORIN A; ETRETIN; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; KERATOLYTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; DATA BASE; DERMATOLOGIST; ECTOPIC PREGNANCY; FEMALE; GENERAL PRACTITIONER; HOSPITALIZATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL ABORTION; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT; PHOTOTHERAPY; PREGNANCY; PREGNANCY TEST; PREGNANT WOMAN; PRIORITY JOURNAL; PRIVATE PRACTICE; PSORIASIS; PUVA; REIMBURSEMENT; RISK FACTOR; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY; URINALYSIS; YOUNG ADULT; ABNORMALITIES, DRUG-INDUCED; CONTRACEPTIVE BEHAVIOR; FAMILY PLANNING; FRANCE; PRACTICE GUIDELINE; STATISTICS AND NUMERICAL DATA;

ABNORMALITIES, DRUG-INDUCED; ACITRETIN; ADOLESCENT; ADULT; CONTRACEPTION BEHAVIOR; FAMILY PLANNING SERVICES; FEMALE; FRANCE; GUIDELINE ADHERENCE; HUMANS; KERATOLYTIC AGENTS; MIDDLE AGED; YOUNG ADULT;

EID: 84928205534     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3763     Document Type: Article

References (29)

1. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merliere Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique Aug 2010; 58(4): 286-290.
2. Lee MR, Cooper AJ. Immunopathogenesis of psoriasis. Australas J Dermatol Aug 2006; 47(3): 151-159.
3. Koo J, Lee E, Lee CS, Lebwohl M. Psoriasis. J Am Acad Dermatol Apr 2004; 50(4): 613-622.
4. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol Feb 2013; 133(2): 377-385.
5. Howard WBWC. Toxicology of retinoids in humans and animals. J Toxicol Toxin Rev 1986; 5: 55-64.
6. Willhite CC, Hill RM, Irving DW. Isotretinoin-induced craniofacial malformations in humans and hamsters. J Craniofac Genet Dev Biol Suppl 1986; 2: 193-209.
7. Barbero P, Lotersztein V, Bronberg R, Perez M, Alba L. Acitretin embryopathy: a case report. Birth Defects Res A Clin Mol Teratol Oct 2004; 70(10): 831-833.
8. Berbis P. Systemic retinoids (acitretin, isotretinoin). Ann Dermatol Venereol Dec 2007; 134(12): 935-941.
9. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen-Kudsk F. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol May 1993; 100(5): 623-627.
10. Lambert WE, Meyer E, De Leenheer AP, De Bersaques J, Kint AH. Pharmacokinetics and drug interactions of etretinate and acitretin. J Am Acad Dermatol Dec 1992; 27(6 Pt 2): S19-22.
11. DiGiovanna JJ, Zech LA, Ruddel ME, Gantt G, Peck GL. Etretinate. Persistent serum levels after long-term therapy. Arch Dermatol Feb 1989; 125(2): 246-251.
12. Lammer EJ, Chen DT, Hoar RM, et al. Retinoic acid embryopathy. N Engl J Med Oct 3 1985; 313(14): 837-841.
13. Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM)-Répertoire des spécialités pharmaceutiques-SmPC Acitretin. 2013; Available at: http://www.agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=60292349 [10 October 2013].
14. Agence Technique de l'information sur l'Hospitalisation (ATIH). 2013; Avlailable at: http://www.atih.sante.fr/ [10 October 2013].
15. Ghasri P, Yentzer BA, Dabade TS, Feldman SR. Acitretin for the treatment of psoriasis: an assessment of national trends. J Drugs Dermatol Aug 2011; 10(8): 873-877.
16. Davis SA, Yentzer BA, Feldman SR. Acitretin prescribing patterns in women of childbearing potential. J Drugs Dermatol Jul 1 2013; 12(7): 799-802.
17. Crijns I, Mantel-Teeuwisse A, Bloemberg R, Pinas E, Straus S, de Jong-van den Berg L. Healthcare professional surveys to investigate the implementation of the isotretinoin Pregnancy Prevention Programme: a descriptive study. Expert Opin Drug Saf Jan 2013; 12(1): 29-38.
18. Boucher N, Beaulac-Baillargeon L. Pregnancy prevention among women taking isotretinoin: failure to comply with the recommendations. Can Fam Physician Mar 2006; 52: 338-339.
19. Cheetham TC, Wagner RA, Chiu G, Day JM, Yoshinaga MA, Wong L. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study. J Am Acad Dermatol Sep 2006; 55(3): 442-448.
20. Mitchell AA, Van Bennekom CM. Accutane and pregnancy. J Am Acad Dermatol Dec 2003; 49(6): 1201-1202.
21. Chan A, Keane RJ, Hanna M, Abbott M. Terminations of pregnancy for exposure to oral retinoids in South Australia, 1985-1993. Aust N Z J Obstet Gynaecol Nov 1995; 35(4): 422-426.
22. Strauss JS, Leyden JJ, Lucky AW, et al. Safety of a new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol Aug 2001; 45(2): 196-207.
23. Autret-Leca E, Kreft-Jais C, Elefant E, et al. Isotretinoin exposure during pregnancy: assessment of spontaneous reports in France. Drug Saf Aug 1 2010; 33(8): 659-665.
24. Berard A, Azoulay L, Koren G, Blais L, Perreault S, Oraichi D. Isotretinoin, pregnancies, abortions and birth defects: a population-based perspective. Br J Clin Pharmacol Feb 2007; 63(2): 196-205.
25. Shin J, Cheetham TC, Wong L, et al. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system. J Am Acad Dermatol Dec 2011; 65(6): 1117-1125.
26. Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM)-Répertoire des Spécialités médicales-SmPc Isotretinoin. 2013; Available at: http://www.agence-prd.ansm.sante.fr/php/ecodex/index.php#result [10 October 2013].
27. Fagot JP, Blotiere PO, Ricordeau P, Weill A, Alla F, Allemand H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: a French nationwide cohort study based on national administrative databases. Diabetes Care Feb 2013; 36(2): 294-301.
28. Weill A, Paita M, Tuppin P, et al. Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol Drug Saf Dec 2010; 19(12): 1256-1262.
29. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia Jul 2012; 55(7): 1953-1962.